CD4 and pneumocystosis: Cotrimoxazole (CTX) has been recommended as prophylaxis against Pneumocystis jiroveci pneumonia (PJP), toxoplasmosis, malaria and other serious bacterial infections in adults with severe or advanced HIV clinical disease, with a CD4 count less than 350 cells/μL or less than 200 cells/μL (depending on region), by the World Health Organization (WHO) 1, 2.